Canadian Guideline Updates That Will Appear on Your 2026 CCFP Exam
Guidelines change. Exams test current practice. Here are the major Canadian guideline updates from 2024–2026 that you need to know for the upcoming CCFP certification exam.
⚠️ Exam tip: Guideline changes are high-yield because they test whether candidates are practicing current medicine — not medicine from 5 years ago. If a guideline changed recently, expect it to appear.
🔴 Type 2 Diabetes: The Paradigm Shift
Source: Diabetes Canada Clinical Practice Guidelines 2024 + NICE NG28 Update
What changed:
- SGLT2 inhibitors are now first-line for patients with established cardiovascular disease, heart failure, or CKD — regardless of A1C
- GLP-1 receptor agonists also first-line for the same populations
- Metformin remains first-line for most patients WITHOUT cardiorenal comorbidity
- The decision is no longer just “start metformin” — it's “does this patient have CVD, HF, or CKD?”
Exam scenario to expect:
“62-year-old with T2DM, A1C 7.8%, and known coronary artery disease, currently on metformin. What do you add?”
Answer: SGLT2 inhibitor (empagliflozin or dapagliflozin) or GLP-1 RA (semaglutide or liraglutide) for cardioprotection — NOT a sulfonylurea or DPP-4i.
🔴 Sepsis: Complete Overhaul
Source: NICE NG253/254/255 (February 2026) — replaces NG51
What changed:
- Three separate guidelines now replace the single NG51: recognition, community management, and hospital management
- NEWS2 score integrated more formally into sepsis recognition
- Emphasis on structured clinical assessment rather than SIRS criteria
- Updated antibiotic timing recommendations
While these are NICE (UK) guidelines, the principles inform Canadian practice and the CCFP exam may test the underlying concepts: rapid recognition, fluid resuscitation, early antibiotics, and lactate measurement.
🟡 Asthma: Updated Stepwise Approach
Source: NICE NG245 (2024) + GINA 2024
What changed:
- ICS-formoterol as reliever is now established at multiple steps — not just SABA PRN
- SABA-only treatment (without ICS) is no longer recommended even for mild intermittent asthma
- Maintenance and reliever therapy (MART) with budesonide-formoterol is preferred for Steps 3-4
- Biologic threshold lowered — earlier consideration in severe asthma
Key exam point: If a patient is using SABA more than 2x/week, they need an ICS. The old approach of “SABA PRN for mild asthma” is outdated.
🟡 Obesity: New Pharmacotherapy Evidence
Source: CFP Vol 71, Nov/Dec 2025 — Tirzepatide and semaglutide articles
What changed:
- Tirzepatide 15 mg achieves 22.5% weight loss vs 2.4% placebo at 72 weeks (NNT=2 for >5% loss)
- Semaglutide 2.4 mg achieves ~15% weight loss at 68 weeks
- Lean mass loss is a concern — nutrition and exercise remain mandatory adjuncts
- Both agents have cardiovascular benefits independent of weight loss
Key exam point: Know the drugs, their efficacy, AND the caveat about lean mass loss. The exam will likely pair obesity with comorbidities (T2DM, CVD) where these agents serve dual purposes.
🟡 Meningitis: Updated Recognition
Source: NICE NG240 (2024)
What changed:
- Updated recognition criteria and pre-hospital management
- Emphasis on not delaying antibiotics for investigations
- Clarified LP contraindications (focal deficits, GCS <12, signs of raised ICP)
- Dexamethasone timing reaffirmed: BEFORE or WITH first antibiotic dose
🟡 Falls Prevention in Older Adults
Source: NICE NG249 (August 2025)
What changed:
- Multifactorial risk assessment for all adults 65+ who present with a fall
- Medication review (especially sedatives, antihypertensives, anticholinergics)
- Exercise programs (strength + balance) as primary prevention
- Home hazard assessment for recurrent fallers
🟢 Other Updates to Know
| Topic | Key Change | Source |
|---|---|---|
| Vitamin B12 deficiency | New diagnostic pathway; oral replacement preferred over IM | NICE NG239 (2024) |
| Adrenal insufficiency | First NICE guideline — recognition in primary care | NICE NG243 (2024) |
| Pneumonia (community) | Updated antibiotic choices and severity scoring | NICE NG250 (Sept 2025) |
| Cervical screening | HPV primary screening replacing cytology in more provinces | Provincial guidelines 2025 |
How to Stay Current
- Read CFP articles — Canadian Family Physician publishes clinical reviews and “Tools for Practice” articles that directly support Priority Topic preparation.
- Check Diabetes Canada, Hypertension Canada, and CCS annually — these three organizations produce the guidelines most commonly tested on the CCFP exam.
- Follow CTFPHC recommendations — the Canadian Task Force on Preventive Health Care sets screening guidelines (breast, colon, cervical, lung cancer screening).
- Practice with updated content — use question banks that reflect current guidelines, not questions written 5 years ago.
💡 SampQs reflects 2025–2026 guidelines
Every marking scheme in SampQs is built against current Canadian guidelines. When guidelines change, our content updates. You'll never lose marks for following last year's recommendations.
Start practicing with current guidelines →Written by the SampQs team — physicians who've taken the CCFP exam and built a better way to prepare for it.